[Pulmonary complications of Chronic Granulomatous Disease].

Complications pulmonaires de la granulomatose septique chronique.
Aspergillus Chronic Granulomatous Disease Déficit immunitaire héréditaire Granulomatose septique chronique Inflammation NADPH oxidase NADPH oxydase Primary immunodeficiency

Journal

Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032

Informations de publication

Date de publication:
24 Jan 2024
Historique:
received: 22 02 2023
accepted: 05 12 2023
medline: 26 1 2024
pubmed: 26 1 2024
entrez: 25 1 2024
Statut: aheadofprint

Résumé

Chronic Granulomatosis Disease (CGD) is an inherited immune deficiency due to a mutation in the genes coding for the subunits of the NADPH oxidase enzyme that affects the oxidative capacity of phagocytic cells. It is characterized by increased susceptibility to bacterial and fungal infections, particularly Aspergillus, as well as complications associated with hyperinflammation and granulomatous tissue infiltration. There exist two types of frequently encountered pulmonary manifestations: (1) due to their being initially pauci-symptomatic, possibly life-threatening infectious complications are often discovered at a late stage. Though their incidence has decreased through systematic anti-bacterial and anti-fungal prophylaxis, they remain a major cause of morbidity and mortality; (2) inflammatory complications consist in persistent granulomatous mass or interstitial pneumoniae, eventually requiring immunosuppressive treatment. Pulmonary complications recurring since infancy generate parenchymal and bronchial sequelae that impact functional prognosis. Hematopoietic stem cell allograft is a curative treatment; it is arguably life-sustaining and may limit the morbidity of the disease. As a result of improved pediatric management, life expectancy has increased dramatically. That said, new challenges have appeared with regard to adults: difficulties of compliance, increased inflammatory manifestations, acquired resistance to anti-infectious therapies. These different developments underscore the importance of the transition period and the need for multidisciplinary management.

Identifiants

pubmed: 38272769
pii: S0761-8425(24)00002-0
doi: 10.1016/j.rmr.2024.01.002
pii:
doi:

Types de publication

English Abstract Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

H Salvator (H)

Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France; UMR0892 VIM-Suresnes Inrae, université Paris-Saclay, Suresnes, France; Faculté de Sciences de la Vie Simone Veil, Université Versailles Saint Quentin, Montigny-le-Bretonneux, France. Electronic address: h.salvator@hopital-foch.com.

N Mahlaoui (N)

Centre de référence déficits immunitaires héréditaires (CEREDIH), hôpital Necker-Enfants Malades, institut Imagine, université Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France; Service d'hématologie-immunologie et rhumatologie pédiatrique, hôpital Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Paris, France.

F Suarez (F)

Centre de référence déficits immunitaires héréditaires (CEREDIH), hôpital Necker-Enfants Malades, institut Imagine, université Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France; Service d'hématologie adultes, hôpital Necker-Enfants Malades, université Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France.

A Marcais (A)

Service d'hématologie adultes, hôpital Necker-Enfants Malades, université Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France.

E Longchampt (E)

Service d'anatomopathologie, hôpital Foch, Suresnes, France.

C Tcherakian (C)

Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.

C Givel (C)

Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.

A Chabrol (A)

Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.

E Caradec (E)

Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.

O Lortholary (O)

Service de maladies infectieuses, hôpital Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Paris, France; Centre national de référence des mycoses invasives et antifongiques, Centre national de la recherche scientifique, unite mixté de recherche (UMR) 2000, Institut Pasteur, université Paris Cité, Paris, France.

F Lanternier (F)

Service de maladies infectieuses, hôpital Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Paris, France; Centre national de référence des mycoses invasives et antifongiques, Centre national de la recherche scientifique, unite mixté de recherche (UMR) 2000, Institut Pasteur, université Paris Cité, Paris, France.

C Goyard (C)

Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.

L J Couderc (LJ)

Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France; UMR0892 VIM-Suresnes Inrae, université Paris-Saclay, Suresnes, France.

E Catherinot (E)

Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.

Classifications MeSH